ORIL has developed a unique anticancer drug with outstanding market potential
Platform technology based on a first-in-class mode of action that targets the cancer cell membrane
Focus on currently-untreatable cancers using plant-based medicines
Lead compound optimised with preclinical studies progressing towards a Phase I study planned for completion within 18 months
Strong IP Position with 4 patents granted, or in national phase, in lead markets
Product pipeline in other therapeutic areas, based on platform technology
Internationally focused product registration strategy for the lead oncology product with defined path to market linked to clear milestones
Internationally recognised Board, management and advisory teams with a unique blend of experience and substantial track records in the biotech industry.
